ImmuCell Corporation
We are preparing, please wait
Undervalued or Overvalued?
Unfortunately, this content is only accessible to registered users
Login to ContinueKey stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Market Cap
$35.08 M
Change
$0.43
EPS
-$0.51
P/E Growth
-8.8
56 Evergreen Drive, Portland, ME, 04103
Sector:
Industry:
Fiscal Year-end
December
Revenue
$17.47 M
Net Income
$-5,774,598
2023 Sales Growth
-5.90%
ImmuCell Corporation's CEO, Mr. Michael F. Brigham
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
An income statement known as a profit and loss statement, is a financial report that summarizes a company's revenues, expenses, gains, and losses over a specific period. It provides insight into a company's operational efficiency and profitability, helping investors and stakeholders assess financial performance and make informed decisions.
The Financials Balance Sheet report provides a clear and concise visual summary of a company’s financial standing through interactive charts. This section highlights key components such as assets, liabilities, and equity, offering investors an at-a-glance understanding of the company's financial health. By showcasing these critical metrics in an easy-to-digest format, the report enables stakeholders to evaluate the company’s stability, operational efficiency, and capital structure, fostering more informed investment decisions.
The Financials Cash Flow report uses charts to provide a clear breakdown of a company’s cash flow across operating, investing, and financing activities. This visualization helps investors quickly assess how the company generates, spends, and manages cash, offering valuable insights into its liquidity and financial efficiency.
Market Benchmark Score
Market Score: Aggregate the average P/E ratio of all companies in the market.
Industry Score: Aggregate the average P/E ratio of all companies in the same industry.
ASSETS
$43.81 M
LIABILITIES
$18.82 M
DEBT Equity Ratio
0.41
Operating Cash Flow
$-4,674,236
The latest Technical Analysis Summary on Stocks.News offers insights into market trends using key Technical Indicators like RSI and MACD, alongside Moving Averages such as the 50-day and 200-day. The analysis identifies buy and sell signals through bullish or bearish crossovers, helping investors make informed trading decisions.
Today's price of ImmuCell Corporation is $4.96 — it has increased by +9.49%
Yes, you can track ImmuCell Corporation's financials in yearly and quarterly reports directly on Stocks.News.
Watch the ImmuCell Corporation chart and read a more detailed ImmuCell Corporation stock forecast to see what analysts suggest you do with its shares.
The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by ImmuCell Corporation stock ticker.
Like other stocks, ICCC shares are sold on stock exchanges such as NASDAQ The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.
ImmuCell Corporation measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in ImmuCell Corporation’s financial statements.
